MINNEAPOLIS--(BUSINESS WIRE)--In the largest, randomized, controlled study of deep brain stimulation (DBS) for Parkinson’s disease, Medtronic DBS Therapy was shown to improve motor function for up to two years in patients with advanced Parkinson’s disease, showing equally strong efficacy for the two most common surgical targets used for the therapy. The study, conducted at seven Veterans Affairs and six university hospitals with participation from 299 patients, compared the 24-month results of patients assigned randomly to receive DBS via one of the two common targets in the brain – the subthalamic nucleus (STN) or globus pallidus interna (GPi). The findings are published in the June 3 issue of The New England Journal of Medicine.
